誉衡药业 (002437.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

16.5x

Market Cap

CNY 8.79B

MomentumView details →

1D Return

−9.43%

YTD Return

+28.34%

RSI (14)

49.1

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

16.5x

Market Cap

CNY 8.79B

RSI (14)

49.1

MomentumView details →

1D Return

−9.43%

YTD Return

+28.34%

ProfitabilityView details →

Gross Margin

44.48%

Net Margin

19.38%

EBITDA Margin

23.28%

ROE (TTM)

17.24%

ROA (TTM)

13.10%

Asset Turnover

0.68x

GrowthView details →

Revenue YoY

−11.49%

EPS YoY

+72.52%

FCF YoY

−27.78%

Revenue CAGR 3Y

−11.76%

EPS CAGR 3Y

+77.27%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

1.90x

Quick Ratio

1.61x

Div Yield

—

Div Rate

—

Div Growth 1Y

−20.00%

Financials snapshotView financials →

Revenue (TTM)

2.12B

Net Income (TTM)

411.58M

Op. CF (TTM)

239.59M

Latest newsMore news →

Yuhuan Pharmaceutical announced its first-half 2026 results: net profit attributable to shareholders was 159 million yuan, up 18.27% year-on-year, with revenue of 1.007 billion yuan, down 8.41%.9d ago

Similar companies

力合科创002243.SZ 漫步者002351.SZ 中利集团002309.SZ 水羊股份300740.SZ 慧翰股份301600.SZ 青鸟智控002960.SZ Find similar companies →

Latest newsMore news →

Yuhuan Pharmaceutical announced its first-half 2026 results: net profit attributable to shareholders was 159 million yuan, up 18.27% year-on-year, with revenue of 1.007 billion yuan, down 8.41%.9d ago